PTH(1-34) for the primary prevention of postthyroidectomy hypocalcemia: The THYPOS trial

Andrea Palermo, Giuseppe Mangiameli, Gaia Tabacco, Filippo Longo, Claudio Pedone, Silvia Irina Briganti, Daria Maggi, Fabio Vescini, Anda Naciu, Angelo Lauria Pantano, Nicola Napoli, Silvia Angeletti, Paolo Pozzilli, Pierfilippo Crucitti, Silvia Manfrini

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Context: There are no studies evaluating teriparatide for prevention of post-thyroidectomy hypocalcemia. Objective: Our objective was to evaluate whether teriparatide can prevent postsurgical hypocalcemia and shorten the hospitalization in subjects at high risk of hypocalcemia following thyroid surgery. Design: This was a prospective phase II randomized open-label trial. Setting: This trial was set on a surgical ward. Patients: Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included. Intervention: Subjects were randomized (1:1) to receive SC administration of 20mcgof teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group). Main Outcome Measure: Adjusted serum calcium, duration of hospitalization, and calcium/calcitriol supplementation were measured. Results: Overall, the incidence of hypocalcemia was 3/13 in treatment group and 11/13 in the control group (P = .006). Treated patients had a lower risk of hypocalcemia than controls (relative risk, 0.26 [95% confidence interval, 0.09-0.723)]). The median duration of hospitalization was 3 days (interquartile range, 1) in control subjectsand2 days (interquartile range, 0) in treated subjects P= .012). One month after discharge, 10/13 subjects in the treatment group had stopped calcium carbonate supplements, while only 5/13 in the control group had discontinued calcium. The ANOVA for repeated measures showed a significant difference in calcium supplements between groups at 1-month visit P= .04) as well as a significant difference between discharge and 1-month visit in the treatment group (P for interaction time group = .04) Conclusions: Teriparatide may prevent postsurgical hypocalcemia, shorten the duration of hospitalization, and reduce the need for calcium and Vitamin D supplementation after discharge in high risk subjects after thyroid surgery. (J Clin Endocrinol Metab 101: 4039-4045, 2016).

Original languageEnglish
Pages (from-to)4039-4045
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume101
Issue number11
DOIs
Publication statusPublished - Nov 1 2016
Externally publishedYes

Fingerprint

Hypocalcemia
Teriparatide
Primary Prevention
Parathyroid Hormone
Calcium
Hospitalization
Surgery
Thyroidectomy
Control Groups
Thyroid Gland
Calcium Carbonate
Calcitriol
Analysis of variance (ANOVA)
Vitamin D
Therapeutics
Labels
Analysis of Variance
Outcome Assessment (Health Care)
Confidence Intervals
Incidence

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Palermo, A., Mangiameli, G., Tabacco, G., Longo, F., Pedone, C., Briganti, S. I., ... Manfrini, S. (2016). PTH(1-34) for the primary prevention of postthyroidectomy hypocalcemia: The THYPOS trial. Journal of Clinical Endocrinology and Metabolism, 101(11), 4039-4045. https://doi.org/10.1210/jc.2016-2530

PTH(1-34) for the primary prevention of postthyroidectomy hypocalcemia : The THYPOS trial. / Palermo, Andrea; Mangiameli, Giuseppe; Tabacco, Gaia; Longo, Filippo; Pedone, Claudio; Briganti, Silvia Irina; Maggi, Daria; Vescini, Fabio; Naciu, Anda; Pantano, Angelo Lauria; Napoli, Nicola; Angeletti, Silvia; Pozzilli, Paolo; Crucitti, Pierfilippo; Manfrini, Silvia.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 101, No. 11, 01.11.2016, p. 4039-4045.

Research output: Contribution to journalArticle

Palermo, A, Mangiameli, G, Tabacco, G, Longo, F, Pedone, C, Briganti, SI, Maggi, D, Vescini, F, Naciu, A, Pantano, AL, Napoli, N, Angeletti, S, Pozzilli, P, Crucitti, P & Manfrini, S 2016, 'PTH(1-34) for the primary prevention of postthyroidectomy hypocalcemia: The THYPOS trial', Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 11, pp. 4039-4045. https://doi.org/10.1210/jc.2016-2530
Palermo, Andrea ; Mangiameli, Giuseppe ; Tabacco, Gaia ; Longo, Filippo ; Pedone, Claudio ; Briganti, Silvia Irina ; Maggi, Daria ; Vescini, Fabio ; Naciu, Anda ; Pantano, Angelo Lauria ; Napoli, Nicola ; Angeletti, Silvia ; Pozzilli, Paolo ; Crucitti, Pierfilippo ; Manfrini, Silvia. / PTH(1-34) for the primary prevention of postthyroidectomy hypocalcemia : The THYPOS trial. In: Journal of Clinical Endocrinology and Metabolism. 2016 ; Vol. 101, No. 11. pp. 4039-4045.
@article{b163d0e3f59e4d1da535ad816a60825d,
title = "PTH(1-34) for the primary prevention of postthyroidectomy hypocalcemia: The THYPOS trial",
abstract = "Context: There are no studies evaluating teriparatide for prevention of post-thyroidectomy hypocalcemia. Objective: Our objective was to evaluate whether teriparatide can prevent postsurgical hypocalcemia and shorten the hospitalization in subjects at high risk of hypocalcemia following thyroid surgery. Design: This was a prospective phase II randomized open-label trial. Setting: This trial was set on a surgical ward. Patients: Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included. Intervention: Subjects were randomized (1:1) to receive SC administration of 20mcgof teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group). Main Outcome Measure: Adjusted serum calcium, duration of hospitalization, and calcium/calcitriol supplementation were measured. Results: Overall, the incidence of hypocalcemia was 3/13 in treatment group and 11/13 in the control group (P = .006). Treated patients had a lower risk of hypocalcemia than controls (relative risk, 0.26 [95{\%} confidence interval, 0.09-0.723)]). The median duration of hospitalization was 3 days (interquartile range, 1) in control subjectsand2 days (interquartile range, 0) in treated subjects P= .012). One month after discharge, 10/13 subjects in the treatment group had stopped calcium carbonate supplements, while only 5/13 in the control group had discontinued calcium. The ANOVA for repeated measures showed a significant difference in calcium supplements between groups at 1-month visit P= .04) as well as a significant difference between discharge and 1-month visit in the treatment group (P for interaction time group = .04) Conclusions: Teriparatide may prevent postsurgical hypocalcemia, shorten the duration of hospitalization, and reduce the need for calcium and Vitamin D supplementation after discharge in high risk subjects after thyroid surgery. (J Clin Endocrinol Metab 101: 4039-4045, 2016).",
author = "Andrea Palermo and Giuseppe Mangiameli and Gaia Tabacco and Filippo Longo and Claudio Pedone and Briganti, {Silvia Irina} and Daria Maggi and Fabio Vescini and Anda Naciu and Pantano, {Angelo Lauria} and Nicola Napoli and Silvia Angeletti and Paolo Pozzilli and Pierfilippo Crucitti and Silvia Manfrini",
year = "2016",
month = "11",
day = "1",
doi = "10.1210/jc.2016-2530",
language = "English",
volume = "101",
pages = "4039--4045",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "11",

}

TY - JOUR

T1 - PTH(1-34) for the primary prevention of postthyroidectomy hypocalcemia

T2 - The THYPOS trial

AU - Palermo, Andrea

AU - Mangiameli, Giuseppe

AU - Tabacco, Gaia

AU - Longo, Filippo

AU - Pedone, Claudio

AU - Briganti, Silvia Irina

AU - Maggi, Daria

AU - Vescini, Fabio

AU - Naciu, Anda

AU - Pantano, Angelo Lauria

AU - Napoli, Nicola

AU - Angeletti, Silvia

AU - Pozzilli, Paolo

AU - Crucitti, Pierfilippo

AU - Manfrini, Silvia

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Context: There are no studies evaluating teriparatide for prevention of post-thyroidectomy hypocalcemia. Objective: Our objective was to evaluate whether teriparatide can prevent postsurgical hypocalcemia and shorten the hospitalization in subjects at high risk of hypocalcemia following thyroid surgery. Design: This was a prospective phase II randomized open-label trial. Setting: This trial was set on a surgical ward. Patients: Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included. Intervention: Subjects were randomized (1:1) to receive SC administration of 20mcgof teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group). Main Outcome Measure: Adjusted serum calcium, duration of hospitalization, and calcium/calcitriol supplementation were measured. Results: Overall, the incidence of hypocalcemia was 3/13 in treatment group and 11/13 in the control group (P = .006). Treated patients had a lower risk of hypocalcemia than controls (relative risk, 0.26 [95% confidence interval, 0.09-0.723)]). The median duration of hospitalization was 3 days (interquartile range, 1) in control subjectsand2 days (interquartile range, 0) in treated subjects P= .012). One month after discharge, 10/13 subjects in the treatment group had stopped calcium carbonate supplements, while only 5/13 in the control group had discontinued calcium. The ANOVA for repeated measures showed a significant difference in calcium supplements between groups at 1-month visit P= .04) as well as a significant difference between discharge and 1-month visit in the treatment group (P for interaction time group = .04) Conclusions: Teriparatide may prevent postsurgical hypocalcemia, shorten the duration of hospitalization, and reduce the need for calcium and Vitamin D supplementation after discharge in high risk subjects after thyroid surgery. (J Clin Endocrinol Metab 101: 4039-4045, 2016).

AB - Context: There are no studies evaluating teriparatide for prevention of post-thyroidectomy hypocalcemia. Objective: Our objective was to evaluate whether teriparatide can prevent postsurgical hypocalcemia and shorten the hospitalization in subjects at high risk of hypocalcemia following thyroid surgery. Design: This was a prospective phase II randomized open-label trial. Setting: This trial was set on a surgical ward. Patients: Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included. Intervention: Subjects were randomized (1:1) to receive SC administration of 20mcgof teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group). Main Outcome Measure: Adjusted serum calcium, duration of hospitalization, and calcium/calcitriol supplementation were measured. Results: Overall, the incidence of hypocalcemia was 3/13 in treatment group and 11/13 in the control group (P = .006). Treated patients had a lower risk of hypocalcemia than controls (relative risk, 0.26 [95% confidence interval, 0.09-0.723)]). The median duration of hospitalization was 3 days (interquartile range, 1) in control subjectsand2 days (interquartile range, 0) in treated subjects P= .012). One month after discharge, 10/13 subjects in the treatment group had stopped calcium carbonate supplements, while only 5/13 in the control group had discontinued calcium. The ANOVA for repeated measures showed a significant difference in calcium supplements between groups at 1-month visit P= .04) as well as a significant difference between discharge and 1-month visit in the treatment group (P for interaction time group = .04) Conclusions: Teriparatide may prevent postsurgical hypocalcemia, shorten the duration of hospitalization, and reduce the need for calcium and Vitamin D supplementation after discharge in high risk subjects after thyroid surgery. (J Clin Endocrinol Metab 101: 4039-4045, 2016).

UR - http://www.scopus.com/inward/record.url?scp=84994850596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994850596&partnerID=8YFLogxK

U2 - 10.1210/jc.2016-2530

DO - 10.1210/jc.2016-2530

M3 - Article

AN - SCOPUS:84994850596

VL - 101

SP - 4039

EP - 4045

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -